With the presence of several major players, the global
Behcet's disease therapeutics market is fragmented.
OTEZLA is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with
Behcet's Disease. Since its initial FDA approval in 2014, OTEZLA has been prescribed to more than 250,000 patients with moderate to severe plaque psoriasis or active psoriatic arthritis in the U.S.4
Neurological manifestations of
Behcet's disease. Saudi Med J 2006;27: 1542-6.
Demographic and clinical properties of juvenile-onset
Behcet's disease: a controlled multicenter study.
Pulmonary involvement in
Behcet's disease. Respiration 2008;75:310-21.
Conclusion:
Behcet's Disease patients needed effective symptom management.
[12] International Study Group for
Behcet's Disease, "Criteria for diagnosis of
Behcet's disease," The Lancet, vol.
As s-TREM-1, VEGF-B, and VEGF-B gene expressions may have a role in the pathogenesis of BD, we aimed to investigate the association of VEGF-B and VEGF gene expressions and sTREM-1 levels with
Behcet's disease activity in this study.
The common ocular manifestations of
Behcet's disease which potentially threaten vision include anterior and posterior uveitis, vitritis, panuveitis, retinal vasculitis, papillitis, and chorioretinitis.
and Girasoli et al., can be found in patients with Wegener's granulomatosis, systemic lupus erythematosus, Cogan's syndrome, relapsing polychondritis, polyarteritis nodosa, Sjogren's syndrome, myasthenia gravis,
Behcet's disease, Takayasu's arteritis, rheumatoid arthritis, and other autoimmune conditions.
Behcet's disease (BD) is a chronic inflammatory disease that occurs with relapses and can cause multisystem involvement, and its etiology is not known (1).